Convergence and Personalized Medicine
Greg Yap is Senior Vice President and Lifecycle Leader for Advanced Staining Assays at Ventana Medical Systems. In this role, Greg is responsible for Ventana’s 450 million dollar cancer diagnostic testing business. Ventana’s tests are the market leaders and are used to help guide treatment for over 6 million cancer patients each year worldwide. Previously, Greg was Chief Operating Officer at Cellective Dx, a circulating tumor cell company, and held multiple senior operating roles at Affymetrix.
MSDx: Company Presentation
MSDx, Inc .provides novel biomarker tools for studying disease processes. The company is focused on commercializing both Research Use Only (RUO) and In VitroDiagnostic (IVD) blood test products that will be used in monitoring neurological, autoimmune, and inflammatory disorders.